In an AI hype-filled biopharma industry, one company is taking a back-to-basics yet supercomputer-powered approach — using Bayesian analysis on massive patient datasets to guide drug discovery. The company crunches trillions of data points per patient. “It’s massive, which is why we use a supercomputer,” said Niven R. Narain, Ph.D., BPGbio CEO. The company has…